Načítá se...
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
BACKGROUND: Randomized controlled trials (RCT) generalizability may be limited due to strict patient selection. OBJECTIVE: In a real‐world heart failure (HF) population, we assessed eligibility for sacubitril/valsartan based on PARADIGM‐HF (sacubitril/valsartan effective)/PARAGON‐HF [sacubitril/vals...
Uloženo v:
| Vydáno v: | J Intern Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7984286/ https://ncbi.nlm.nih.gov/pubmed/32776357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13165 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|